Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Psoriasis × baricitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Skin Diseases, Papulosquamous 1 Skin Diseases 1 Psoriasis 1 Plaque, Amyloid 1 Lymphoma, Follicular 1 Bronchiolitis Obliterans Syndrome 1 Arthritis, Rheumatoid 1

Interventions

tofacitinib 7 Etanercept 3 deucravacitinib 2 Methotrexate 2 Adalimumab 2 sotrastaurin 1 secukinumab 1 calcipotriene 1 baricitinib 1 apremilast 1 Anti-Infective Agents, Local 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01490632 2019-09-27

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Eli Lilly and Company

Phase 2 Completed

271 enrolled 32 charts

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous, Plaque, Amyloid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡